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Renal cell carcinoma (RCC) diagnosis is mostly achieved incidentally by imaging provided for unrelated clinical reasons. The
surgical management of localized tumors has reported excellent results. The therapy of advanced RCC has evolved considerably
over recent years with the widespread use of the so-called “targeted therapies.” The identification of molecular markers in body
fluids (e.g., sera and urine), which can be used for screening, diagnosis, follow-up, and monitoring of drug-based therapy in RCC
patients, is one of the most ambitious challenges in oncologic research. Although there are some promising reports about potential
biomarkers in sera, there is limited available data regarding urine markers for RCC.The following review reports some of the most
promising biomarkers identified in the biological fluids of RCC patients.
1. Background
Although advances in imaging techniques during the last
decades have helped in the diagnosis of renal cell carcinomas,
most of these malignancies are detected at an advanced stage
due to their asymptomatic nature [1].
Renal cell carcinoma (RCC) is the ninth most common
malignancy worldwide and evenmore common in developed
countries (up to 6% of all cancers), with a peak of incidence
occurring between 60 and 70 years of age, with a 3 : 2
male : female ratio [2, 3].
The urologic community is focusing on new therapeutic
options, such as nephron-sparing surgical approaches and
ablative procedures for smaller renal masses [4–7].
Since RCCs are often only incidentally diagnosed during
imaging investigations for nonspecific symptoms or other
abdominal disease, a more efficient early diagnosis technique
is urgently required.
1.1. Risk Factors. In the risk evaluation of renal cell car-
cinoma, several genetic, clinical, and environmental fac-
tors have been identified [8–10]. Major risk factors include
cigarette smoking (1/3 of all kidney cancers), alcohol use,
hypertension, and obesity (with a linear correlation between
increased body weight and RCC risk), as well as occupational
and environmental factors (e.g., chronic exposure to cad-
mium, asbestos, petroleumproducts, ionizing radiations, and
acetaminophen abuse) [11–13]. Patients with acquired cystic
kidney disease (ACKD) appear to have an increased risk of
developing RCC masses [14].
Renal carcinoma has also been described in associa-
tion with numerous hereditary diseases (Von Hippel-Lindau
disease, hereditary leiomyomatosis RCC, Birt-Hogg-Dube´
syndrome, hereditary papillary RCC, hereditary nonpoly-
posis colorectal cancer syndrome, and autosomal dominant
polycystic kidney disease) [15, 16].
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1.2. Diagnosis. Diagnosis of renal cell carcinoma is often
difficult since most renal masses remain asymptomatic until
the late stages of the disease [1]. The classic triad of flank
pain, palpable abdominal mass, and gross hematuria is rare
(6–10%), and these signs typically arise at an advanced stage
with aggressive histology [1].
Paraneoplastic syndromes are found in approximately
30% of patients with symptomatic RCCs. A few symptomatic
patients present with symptoms caused bymetastatic disease,
such as bone pain or persistent cough [17].
When such clinical symptoms as well as arousing varic-
ocele or bilateral lower extremity oedema are present, radi-
ological investigation should be applied. Abdominal ultra-
sounds (US) are usually the first imaging procedure per-
formed when RCC is suspected and enables investigators to
distinguish between a benign kidney cyst and a tumor mass
[18, 19].
CT imaging, before and after intravenous contrast, is
useful for verifying the diagnosis and therefore obtaining
information about the contralateral kidney (morphology
and function). CT imaging also assesses tumor extension,
including venous and lymph nodes involvement, as well
as extrarenal spread [20]. In patients with possible venous
involvement or proven allergy to intravenous contrast, MRI
can be used [20]. Percutaneous renal tumour biopsies are
increasingly being used for histological diagnosis of radio-
logic indeterminate renal masses [21].
1.3. Classification. TheTNMclassification system is generally
recommended [22]. The latest version of the TNM classifi-
cation was published in 2010 and this prognostic value of
this classification has been confirmed by single and multi-
institutional studies [23, 24]. However, some of the data
remain controversial: T1 tumour subclassification with the
current cut-off of 4 cm might not be adequately related to
the widening of nephron-sparing surgery; some substages of
the classification (pT2b, pT3a, pT3c, and pT4) may overlap
[24]; the value of size stratification of T2 tumours has been
(and continues to be) a debate [25]; tumours with renal
sinus fat invasion are currently classified as pT3a; however,
an increasing amount of data suggests that renal sinus fat
invasion might be more closely related to a worse prognosis
than perinephric fat invasion; therefore these different forms
of fat invasions should not be classified in the same pT3a stage
group [26].
In 2004, the World Health Organization issued a clas-
sification system for RCC, partially modified in 2013 by
ISUP Vancouver Classification, which recognizes several
histopathological entities. From a clinical point of view, three
main types of RCC are the most important: clear cell (cRCC),
papillary (pRCC), and chromophobe (chRCC) [27].
Clear cell carcinoma takes its name from its histologic
features of a clear-cytoplasm cell surrounded by a dense
endothelial network, and this type of cancer represents about
70% of all kidney cancers. Clear cell carcinoma is associated
with loss of function of the VHL gene, which leads to
hypoxia-inducible factors and Vascular Endothelial Growth
Factor (VEGF), both strictly linked to tumor angiogenesis
[28].
Papillary RCC (pRCC) is the second most common
tumor and two different subtypes of pRCC have been iden-
tified and labelled as pRCC type 1 and pRCC type 2. pRCC
type 1 is believed to be less aggressive than type 2. Diagnosis
is mostly based on the papillary architecture. pRCC features a
basophilic cytoplasm and foamy histiocytes are characteristic
in this kind of neoplasm [29].
Chromophobe RCCs account for about 5% of RCCs and
show the lowest risk of developing metastasis. Chromophobe
RCCs often have an empty cytoplasm, perinuclear clearing,
and a low mitotic rate [30]. Any subtype of RCC may feature
a sarcomatoid dedifferentiation often associated with a more
aggressive behaviour [31].
1.4. Treatment. Partial or radical nephrectomy remains the
gold standard for the management of renal masses [32]. The
use of an anatomical classification system for renal tumours
has been introduced because it allows objective prediction
of potential morbidity of nephron-sparing surgery and focal
techniques.These systems include the assessment of anatom-
ical features: tumour size, exophytic/endophytic properties,
nearness to the collecting system and renal sinus, and anterior
and posterior localisation. The widely used classifications
include the PreoperativeAspects andDimensionsUsed for an
Anatomical (PADUA) score, the RENAL nephrometry score,
and the C-index, which are currently used to standardize the
description of renal tumours [31, 33, 34].
These classification systems are useful in planning
patient’s treatment and counselling and to specifically com-
pare partial nephrectomy and tumour ablation case series. It
should be noted that the anatomic scores, the clinical features,
and the experience of the surgeon have to be considered
together when making decisions about the best therapeutic
strategy for each patient.
Since laparoscopic and robot-assisted radical nephrec-
tomy has been proven to lead to lower morbidity than
open surgical techniques, it has now become an established
procedure [35]. A recently published prospective randomised
clinical trial (RCT) compared radical with partial nephrec-
tomy in solitary T1-2 N0M0 renal tumours <5 cm with
normal contralateral kidney function. The cancer specific
survival (CSS) was 98.5 after radical nephrectomy versus 97%
after nephron-sparing surgery (NSS) [4].
Radical nephrectomy with complete removal of the
interested kidney along with its perirenal fat and Gerota’s
fascia is currently recommended in patients not eligible for
a nephron-sparing approach: a sparing procedure is not
believed to be suitable for patients with an advanced tumor
growth as well as a technically unfavourable localisation of
the tumor itself [36]. When preoperative and intraoperative
findings are normal, an adrenalectomy is not recommended
[37].
Lymphadenectomy should only be considered for staging;
in a recent prospective randomized study only 4% of cN0
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patients had positive lymph nodes at final pathology, sug-
gesting that LND represents overtreatment in the majority of
cases [38].
Unfortunately, adjuvant therapies do not provide signifi-
cant benefits in renal cell carcinoma patients who underwent
surgery.
For patients unsuitable for surgical treatment due to
advanced age or tumour stage, as well as comorbidity that
leads to a higher surgical risk, minimally invasive tech-
niques may be attempted. These procedures include abla-
tive approaches such as radiofrequency ablation, including
microwave ablation, cryoablation, and stereotactic radiation
[6, 7].
Treatment for metastatic RCC consists of cytoreduc-
tive nephrectomy followed by systemic-drug therapy, which
includes immunotherapeutic drugs, antiangiogenic agents,
and mTOR inhibitors [39].
Nephrectomy of the primary tumor is curative only if all
of the tumour deposits are removed. Thus, for patients with
advanced metastatic RCC, nephrectomy is often palliative
[40].
Chemotherapy is not considered effective as a syste-
mic therapy after cytoreductive nephrectomy in metastatic
RCC, while immunotherapy appears effective, although both
interferon-alpha monotherapy and IL-2 monotherapy are
believed to be inferior to targeted therapy. Despite this, IL-2
monotherapy continues to have a role in selected cases [41].
1.5. Prognostic Factors. Postoperative prognostic nomograms
that combine different independent prognostic factors have
been developed and validated [42, 43]. These systems seem
to outperform TNM stage or Fuhrman grade alone for
predicting survival. The most important advantage of these
nomograms is related to their ability to measure predictive
accuracy (PA), which evaluates all newpredictive parameters.
Every new prognostic system should demonstrate its PA
superiority to conventional postoperative histoprognostic
schemes, before being used [44]. Recently, new preoperative
nomograms with excellent PAs have been designed and
adopted [45].
2. Molecular Biomarkers
Histological analysis of TNM stage and the Fuhrman nuclear
grade are the principal currently used independent prognos-
tic factors for clinical work-up of patients. Although almost
all tissue markers studies have been highly promising, almost
all of these are based on retrospective series with small
sample size and relatively short follow-up. The reliability
of the assay used for marker detection represents another
limitation of these studies. In fact, immunohistochemistry
is semiquantitative and highly dependent on a range of
variables, such as choice of antibody, antibody concentration,
fixation techniques, variability in the interpretation and strat-
ification criteria, and inconsistency in specimen handling
and technical procedures. Therefore, the identification of
molecular markers in body fluids (e.g., sera and urine),
which can be used for screening, diagnosis, follow-up, and
monitoring of drug-based therapy in RCC patients, is one of
the most ambitious challenges in oncologic research [46, 47].
The global analysis of gene and protein expression profiles
of biological specimens, like tissue, blood, or urine, is an
emerging promising tool for new biomarker identification.
The markers identified from this high throughput integrated
“omics” technologies have promising potential but appli-
cation in clinical diagnostics and practical improvement
in disease management is extremely rare [48, 49]. Blood
and urine are an ideal source of biomarker, for theoretical,
methodological, and practical reasons [50]. Actually, there
have been some promising reports about potential biomark-
ers in sera, but, to our knowledge, there is scant literaturewith
regard to urine markers for RCC. As such, the available data
are insufficient to justify routine clinical application. Here
we summarize some of the most promising biomarkers for
diverse clinical questions, identified in biological fluids of
RCC patients (Tables 1 and 2).
2.1. Molecular Markers in Serum. There are currently no
serum biomarkers available for accurate diagnosis of RCC.
Some authors identified molecules that can be measured
in serum by noninvasive tests. Using immunoassays, such
as ELISA or immunonephelometry, or mass spectrometry,
authors have detected altered production of serum proteins
in RCC patients, which can provide useful diagnostic and/or
prognostic information.
2.1.1. Tumor Necrosis Factor Receptor-Associated Factor-1
(TRAF-1). TRAF-1 is an adaptor protein involved in the
regulation of cell survival, proliferation, differentiation, and
stress responses. It has been reported that serum levels of
TRAF-1 in RCC patients were significantly increased over
control serum [51].
2.1.2. Heat Shock Protein 27 (Hsp27). Hypoxia, as for inflam-
mation or oxidative stress, represents one of the main
environmental stress conditions that can improve both
tumor initiation and tumor progression. These conditions
determinate, as a consequence, upregulation of some “stress
proteins,” which take part in cellular stress response. Among
these proteins, heat shock proteins play a relevant role as
molecular chaperones for protein folding and unfolding. In
particular, heat shock protein 27 (Hsp27) has been found
to be hyperphosphorylated in many cancer types [52]. In a
recent study, White et al. identified high levels of Hsp27 in
both the serum and the urine of high-grade RCC patients
[53].
2.1.3. Inflammatory Proteins. Several studies have aimed to
clarify the role of inflammatory immune cells and cytokines
in tumorogenic processes of kidney cancer, in order to
develop new immunotherapeutic strategies for the treatment
of this disease. In liver cells, proinflammatory cytokines, such
as IL-1, IL-6, and TNF-𝛼, are able to control the synthesis
of many other inflammation mediators, such as amyloid
A, which is involved in the recruitment of immune cells
to inflammatory sites and the induction of enzymes that
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Table 1: Potential serum biomarkers in RCC.
Marker Author (yr) RCC (number) HC (number) RCC versus HC Stage Grade
TRAF-1 Rajandram et al. (2014) [51] 15 15 ↑
Hsp27 White et al. (2014) [53] 54 36 ↑
SAA Mittal et al. (2012) [55] 422 ↑
Fischer et al. (2012) [56] 115 24 ↑
hsCRP de Martino et al. (2013) [57] 41 ↑ ↑
Steffens et al. (2012) [58] 1.161 ↑
GGT Hofbauer et al. (2014) [60] 921 ↑ ↑
TRAIL Toiyama et al. (2013) [63] 84 52 ↓
M-65 Yildiz et al. (2013) [65] 39 39 ↑
Ab anti-PHD3 Tanaka et al. (2011) [67] 22 26 ↑
CA IX Takacova et al. (2013) [69] 74 ↑
TuM2-PK Nisman et al. (2010) [70] 116 20 ↑ ↑ ↑
TK1 Nisman et al. (2010) [70] 116 20 ↑ ↑
20S proteasome de Martino et al. (2012) [72] 113 15 ↑
OPN Papworth et al. (2013) [74] 269 ↑
RCC: renal cell carcinoma; HC: healthy control; No: number; TRAF-1: tumor necrosis factor receptor-associated Factor-1; Hsp27: heat shock protein 𝛽1;
GGT: Gamma-glutamyl transferase; M65: intact form of CK18; TRAIL: tumor necrosis factor-related apoptosis inducing ligand; CA IX: carbonic anhydrase
IX; hsCRP: high sensitivity C-reactive protein; SAA: serum amyloid A; OPN: osteopontin; anti-PHD3 Ab: anti-hypoxia-inducible factor prolyl hydroxylase-3
antibody; TuM2-PK: pyruvate kinase type M2; TK1: thymidine kinase 1.
Table 2: Potential urinary biomarkers in RCC.
Marker Author (yr) RCC versus CG
NMP-22
Kaya et al. (2005) [76] ↑
Ozer et al. (2002) [77] ↑
Huang et al. (2000) [78] ↑
NGAL Di Carlo (2013) [82] ↑
Morrissey et al. (2011) [83] ↑
KIM-1 Morrissey et al. (2011) [83] ↑
MMPs di Carlo (2012) [84] ↑
AQP-1 Morrissey and Kharasch (2013) [86] ↑
AQP-1 Morrissey et al. (2014) [87] ↑
PLIN2 Morrissey and Kharasch (2013) [86] ↑
PLIN2 Morrissey et al. (2014) [87] ↑
RCC: renal cell carcinoma; CG: control group; NMP-22: nuclear matrix
protein-22; KIM-1: kidney injury molecule-1; MMP: matrix metallopro-
teinases; AQP-1: aquaporin-1; PLIN2: Perilipin 2.
degrade extracellularmatrix [54].Many authors, such asMit-
tal et al. and Fischer et al., identify serum amyloid A (SAA)
as strong new potential biomarkers for RCC, which correlates
positively to tumor stage, particularly in the advanced stages
[55, 56].
Similar to SAA, levels of acute-phase C-reactive pro-
tein (CRP) increase within hours of inflammatory stimulus
(e.g., microbial infection, trauma, infarction, autoimmune, or
malignant diseases). In fact, de Martino et al. and Steffens
et al. observed high serum CRP levels in RCC patients,
associated with T classification and high-grade disease, with
poor survival [57, 58].
Gamma-glutamyl transferase (GGT), an enzyme invol-
ved in glutathione metabolism and whose expression is often
significantly increased in human malignancies, is another
molecular marker of inflammation that is produced mostly
in the liver but also in the kidneys, bile duct, pancreas, and
spleen [59]. Hofbauer et al. identified GGT as a possible
new independent prognostic factor for RCC patients man-
agement, as its levels increase in parallel to tumor staging and
grading [60].
2.1.4. Molecules Involved in Apoptosis. Tumorigenesis pro-
cesses require alterations in physiological apoptotic mech-
anisms, with abnormal activity of antiapoptotic proteins or
inhibition of proapoptotic mediators. In this way, cancer cells
avoid apoptosis and continue to proliferate uncontrollably
[61]. Among themainmolecules involved in the programmed
cell death, the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) has gained interest because it pro-
motes extrinsic apoptosis preferentially in cancer compared
to normal cells [62]. Toiyama et al. revealed a strong decrease
of TRAIL serum levels in RCC patients, before surgery,
compared to control, that was correlated to patients survival
[63].
Moreover, in the circulation of cancer patients, it is
possible to measure apoptosis-derived products, such as
cytokeratins (CK), which are released into the blood in either
intact or caspase-cleaved forms [64]. In particular, Yildiz et al.
found increasing levels of serum M65 (the intact form
of cytokeratin 18) in RCC patients compared to healthy
participants, which could be predictive of their progression-
free survival (PFS) [65].
2.1.5. Molecules Related to Tumor Microenvironment. It has
been wildly reported that tumor mass growth is strictly
controlled by its microenvironment, in which components,
such as fibroblasts and macrophages, release growth factors,
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cytokines, and angiogenic molecules to allow tumor progres-
sion. Hypoxia is an essential factor that characterizes the
environment of tumor renal cells and tumor cells generally.
Hypoxia promotes activation of hypoxia-inducible transcrip-
tional factors (HIF-1𝛼 andHIF-1𝛽) which improve expression
of proangiogenetic factors, such as VEGF [66]. Moreover,
genetic mutations of proteins involved in stabilization of
HIF factors, such as Von Hippel-Lindau (VHL) protein, are
considered the primary events responsible for the occurrence
of the majority of clear cell RCC.
In addition to VHL protein, which is altered in 85% of
RCC cases, the hypoxia-inducible factor prolyl hydroxylase-
3 (PHD3) is frequently overexpressed in kidney cancer tissue
[66]. PHD3 is one member of the PHD family involved in
the degradation of hypoxia-inducible factor (HIF) proteins
in cooperation with VHL. Tanaka et al. observed high levels
of anti-PHD3 Ab titers in the serum of patients with RCC
relative to healthy volunteers, and these levels decreased
after surgical resection [67]. In addition, hypoxia is also able
to promote expression of enzymes, such as carbonic anhy-
drases. These families of metalloenzymes are physiologically
involved in acidification of gastric and renal tissues, but their
synthesis has been reported to be altered in many tumor
types [68]. In particular, Takacova et al. identified a higher
level of carbonic anhydrase IX (CA IX) in both the tissue
and the serum of cRCC patients, compared to non-cRCC
patients. For this reason, this biomarker could represent a
useful variable addictive to histological analysis [69].
2.1.6. Miscellaneous. Nisman et al. detected significantly
higher levels of two enzymes involved in tumor cells
metabolism, pyruvate kinase isoenzyme type M2 (TuM2-
PK), and thymidine kinase 1 (TK1), in RCC patients sera,
compared to controls, and this increase is positively associ-
ated with tumor stage and/or grade [70].
In RCC, as in other cancer types, alteration of physio-
logical ubiquitin proteasome system (UPS) mechanisms has
been observed [71]. de Martino et al. observed an increase in
serum levels of 20S proteasome in RCC patients, compared
to healthy subjects, which are strictly related to their disease-
specific survival (DSS) [72].
Furthermore, about 10% of RCCs feature calcifications
in peritumoral regions. For this reason the measurement
of blood calcium levels is a key analysis used for clinical
diagnosis of RRC. Inmany cases, alterations of hypercalcemia
in RCC are due to changes in the metabolism of inhibitors
and promoters of calcification, such as Fetuin A, Osteopontin
(OPN), and Osteoprotegerin [73]. Papworth et al. showed
that serum OPN was significantly higher in patients with
papillary RCC compared to other RCC histotypes and that
OPN levels were positively correlated with TNM stage and
nuclear grade [74].
2.2. Molecular Markers in Urine. The idea of following
localized tumors ormonitoring drug-based therapy results by
simply analyzing tumor-specific markers in the easily avail-
able excretory products of the kidney is desirable. However,
to the best of our knowledge, there is only scant literature
addressing urine markers for RCC.
2.2.1. Nuclear Matrix Proteins-22 (NMP-22). Nuclear matrix
proteins are part of the internal framework of the nucleus
and are known to have important roles in DNA replication,
transcription of RNA, and regulation of gene expression.
The characteristics of nuclear matrix proteins make them
a potential marker of malignant cells associated with the
abnormal distribution of genetic material and increased
mitosis. Several of the NMPs are organ specific. Cancer-
specific NMPs have been identified in breast, colon, bone,
and urothelium, and NMP-22 has been recognized as a
potential urothelial-specific cancer marker. The prostate-
specific antigen (PSA) for prostate cancer and the urinary
nuclear matrix protein-22 (NMP-22) are the only Federal
Drug Administration- (FDA-) approved screening markers.
Urinary NMP-22 is known to be specific for transitional
cell carcinoma [75], and a rapid flow-through diagnostic test
is available. There are some reports suggesting that NMP-
22 might work as an RCC screening marker [76–78]. Kaya
et al. found that in RCC patients, urinary NMP-22 levels
were significantly higher than those observed in patients
with kidney stones and simple renal cysts used as control
group [76]. Similarly, Ozer et al. and Huang et al. reported
that preoperatively urinary NMP-22 levels were significantly
higher in each of their respective RCC groups than in subjects
with benign renal conditions [77, 78].
2.2.2. Neutrophil Gelatinase-Associated Lipocalin (NGAL).
Lipocalin 2, also known as Neutrophil Gelatinase-Associated
Lipocalin (NGAL), is a prominent member of the lipocalin
family. The lipocalins constitute a large group of small
predominantly extracellular proteins previously regarded as
obscure transporters of hydrophobic ligands ([79, 80] and
ref. therein). In humans, NGAL was originally identified
as a 25 kDa protein covalently linked to matrix metallo-
proteinase-9 (MMP-9) in neutrophils, which normally pro-
vide the main cellular source of circulating NGAL. By
forming the MMP-9/NGAL complex, NGAL protects MMP-
9 from proteolytic degradation, increasing the enzymatic
activity of MMP-9 and subsequently enhancing tumoral
invasiveness and diffusion [81]. NGAL is expressed in the
epithelial cells of the kidney and is involved in kidney
development. NGAL is a biomarker of tubular injury and
is expressed in several histotypes of renal tumor, and its
high expression is associated with higher histological grade
of cRCC, and papillary RCC, whereas oncocytoma and
urothelial carcinoma exhibit lower expression levels. It is
evident that any NGAL systematically released from malig-
nant transformed cells would be freely filtered by the kidney
glomerulus; however, these may be expected to be largely
reabsorbed by efficient endocytic mechanisms in proximal
tubules. Therefore, urinary excretion of NGAL is more
likely to be present in tandem with a concomitant renal
tubular injury that increases de novoNGAL synthesis and/or
precludes NGAL reabsorption. Di Carlo and Morrissey et al.
showed that in cRCC patients the mean value of urinary
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NGAL was higher than that observed in the urine of control
group. However, no correlation with tumor size or stage was
identified in either study [82, 83].
2.2.3. Kidney Injury Molecule-1 (KIM-1). Kidney injury mol-
ecule-1 (KIM-1) is a urinary biomarker of diagnostic rele-
vance in a wide variety of acute and chronic kidney diseases.
However, although KIM-1 has diagnostic sensitivity for kid-
ney cancer, it is well known to reflect many types of kidney
injuries, thus limiting its specificity as a diagnostic marker for
renal cancer [83].
2.2.4. Matrix Metalloproteinases (MMPs). Thematrix metal-
loproteinases (MMPs) are a large group of zinc-containing
endopeptidase with a central role in the degradation of all
types of extracellular matrix (ECM) components. They are
involved in direct and indirect release of growth factors
enhancing tumor growth and tumorigenicity. In particu-
lar, MMP-2 and MMP-9 (also known as gelatinase-A and
gelatinase-B) are most linked to the malignant phenotype of
tumor cells and are commonly used as markers of malignant
cancer. However, despite the tissue evidence, serum and urine
MMP activity seems to be inadequate for identifying renal
cancer ([84] and ref. therein).
2.2.5. Aquaporin-1 (AQP-1) and Perilipin 2 (PLIN2). It
has been shown that aquaporin-1 (AQP-1) and adipocyte-
differentiation-related protein (renamed Perilipin 2 (PLIN2))
are overexpressed in surgical excised renal tumor tissue. On
the basis of the potential for urinary excretion or elimination
of these upregulated proteins, Morrissey et al. found an
elevated urine concentration of AQP-1 and PLIN2 in patients
with clear cell and papillary carcinoma, as compared with
controls [85]. Moreover, the urinary concentrations of these
two markers were not significantly influenced by noncancer-
ous kidney diseases, such as diabetic nephropathy, urinary
tract infection, and glomerulonephritis [86], and reflected the
tumor size and stage [87].
3. Conclusions
Currently, there is no diagnostic modality for early detection
of renal cancer, other than incidental radiologic discovery,
and no method of surveillance of recurrence or response to
chemotherapy. Biomarkers are easily measured substances
that can be used to monitor normal and abnormal biologic
function. Unfortunately, there is no existing biomarker for
kidney cancer diagnosis. The currently available biomarkers
appear to have the most utility as diagnostic adjuncts, as
prognostic indicators, and in following up patients.
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